What kind of German biotechnology start-ups do venture capital companies and corporate investors prefer for equity investments?

Applied Economics

Volumn 38, Issue 5, 2006, Pages 505-518

  Champenois, Claire ^a   Engel, Dirk ^b   Heneric, Oliver ^c  

^a SCIENCES PO   (France)

^b RWI LEIBNIZ INSTITUTE FOR ECONOMIC RESEARCH   (Germany)

^c CENTRE FOR EUROPEAN ECONOMIC RESEARCH ZEW   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ECONOMICS;

EID: 33645543440     PISSN: 00036846     EISSN: None     Source Type: Journal    
DOI: 10.1080/00036840500391146     Document Type: Article

References (45)

1. Almus, M. (2002) What characterizes a fast-growing firm? Applied Economics, 34, pp. 1497-508.
2. Almus, M and Engel, D and Prantl, S. The Mannheim foundation panels of the centre for European economic research ZEW [German and English Version, ZEW-Documentation No. 00-02].Mannheim, 2000.
3. Amit, R and Brander, J and Zott, C. (1998) Why do venture capital firms exist? Theory and Canadian evidence Journal of Business Venturing, 13, pp. 441-66.
4. Brander, J and Amit, R and Antweiler, W. (2002) Venture capital syndication: Improved venture selection versus the value-added hypothesis Journal of Economics and Management, 11, pp. 423-52.
5. Brüderl, J and Preisendörfer, P. (2000) Fast growing businesses. Empirical evidence from a German study International Journal of Sociology, 30, pp. 45-70.
6. Bundesverband deutscher Kapitalbeteiligungsgesellschaften - German Venture Capital Association e. V. BVK.(1998) BVK Statistik 1998. Berlin
7. Bundesverband deutscher Kapitalbeteiligungsgesellschaften-German Venture Capital Association e. V. BVK.(2002a) BVK gründet Arbeitsgruppe Corporate Venture Capital. In Pressemitteilung vom 06.02.2002. Berlin
8. Bundesverband deutscher Kapitalbeteiligungsgesellschaften - German Venture Capital Association e. V. BVK.(2002b) BVK Statistik 2001: Das Jahr 2001 in Zahlen. Berlin
9. Burg, U and Kenney, M. (2000) Venture capital and the birth of the local area networking industry Research Policy, 20, pp. 1111-33.
10. Buse, S.(2000) Wettbewerbsvorteile durch Kooperationen: Erfolgsvoraussetzung für Biotechnologieunternehmen. Wiesbaden
11. Bygrave, WD. (1987) Syndicated investments by venture capital firms: A networking perspective Journal of Business Venturing, 2, pp. 139-54.
12. Carpenter, R and Petersen, B. (2002) Capital market imperfections, high-tech investment, and new equity financing The Economic Journal, 112, pp. 54-72.
13. Casper, S and Kettler, H. (2001) National institutional frameworks and the hybridization of entrepreneurial business models: The German and UK biotechnolgy sectors Industry and Innovation, 8, pp. 5-30.
14. Chan, Y. (1983) On the positive role of financial intermediation in allocation of venture capital in a market with imperfect information Journal of Finance, 38, pp. 1543-68.
15. Diamond, DW. (1984) Financial intermediation and delegated monitoring Review of Economic Studies, 51, pp. 393-414.
16. Gans, JS and Stern, S. (2003) The product market and the market for "ideas": Commercialization strategies for technology entrepreneurs Research Policy, 32, pp. 333-50.
17. Gompers, PA. (2002). Corporations and the financing of innovation: The corporate venturing experience, Economic Review of Federal Reserve Bank of Atlanta, fourth quarter
18. Gompers, PA and Lerner, J. (1998) What drives venture capital fundraising? Brookings Papers on Economic Activity - Microeconomics, pp. 149-92.
19. Gompers, PA and Lerner, J. (2001) The venture capital revolution Journal of Economic Perspectives, 15, pp. 145-68.
20. Gorman, M and Sahlman, WA. (1989) What do venture capitalists do? Journal of Business Venturing, 4, pp. 231-48.
21. Greene, WH.(1997) Econometric Analysis, 3rd edn. Prentice Hall: New York University.
22. Grilli, L. (2005) Internet start-ups access to the bank loan market: evidence from Italy Applied Economics, 37, pp. 293-305.
23. Hamdouch, A and Depret, M-H.(2001) La nouvelle économie industrielle de la pharmacie, Structures industrielles, dynamique d'innovation et stratégies commerciales. Paris
24. Hausmann, J and McFadden, D. (1984) A specification test for the multinomial logit model Econometrica, 52, pp. 1219-40.
25. Hellmann, T and Puri, M. (2000) The interaction between product market and financing strategy: The role of venture capital Review of Financial Studies, 13, pp. 959-84.
26. Hellmann, T and Puri, M. (2002) Venture capital and the professionalization of start-up firms: Empirical evidence Journal of Finance, 57, pp. 169-97.
27. Kortum, S and Lerner, J. (2000) Assessing the contribution of venture capital to innovation RAND Journal of Economics, 31, pp. 674-92.
28. Lerner, J. (1994) The syndication of venture capital investments Financial Management, 23, pp. 16-27.
29. Lerner, J and Shane, H and Tsai, A. (2003) Do equity financing cycles matter? Evidence from biotechnology alliances Journal of Financial Economics, 67, pp. 411-46.
30. Lockett, A and Wright, M. (2001) The syndication of venture capital investments Omega, 29, pp. 375-90.
31. MacMillan, IC and Zemann, L and SubbaNarasimha, PN. (1987) Criteria distinguishing successful from unsuccessful in the venture screening process Journal of Business Venturing, 2, pp. 123-37.
32. McNally, K.(1997) Corporate venture capital, Bridging the equity gap in the small business sector. In. London
33. Myers, SC. (1984) The capital structure puzzle Journal of Finance, 3, pp. 575-92.
34. Nicholson, S and Danzon, P and McCullough, J. Biotech-pharmaceutical alliances as a signal of asset and form quality [NBER Working Paper No. 9007].2002, MA.
35. Norton, E and Tenenbaum, BH. (1993) Specialization versus diversification as a venture capital investment strategy Journal of Business Venturing, 8, pp. 431-42.
36. Ollig W. 2001 Strategiekonzepte für Biotechnologieunternehmen - Gründung, Entwicklungspfade, Geschäftsmodelle. In. Wiesbaden
37. Pisano, GP. (1989) Using equity participation to support exchange: evidence from biotechnology industry Journal of Law, Economics, & Organizations, 5, pp. 109-26.
38. Powell, WW and Koput, KW and Smith-Doerr, L and Owen-Smith, J. (1999) Network position and firm performance: Organizational returns to collaboration in the biotechnology industry Research in the Sociology of Organizations, 16, pp. 129-59.
39. (1998) Pharma 2005. In An Industrial revolution in R&D. Price Waterhouse Coopers.
40. Sahlman WA. (1990) The structure and governance of venture capital organizations Journal of Financial Economic, 27, pp. 473-521.
41. Schween, K.(1996) Corporate venture capital: Risikokapitalfinanzierung deutscher Industrieunternehmen. In. Wiesbaden
42. Storey, DJ. (1994) The role of legal status in influencing bank financing and new firm growth Applied Economics, 26, pp. 129-36.
43. Tyebjee, TT and Bruno, AV. (1984) A model of venturecapitalist investment activity Management Science, 30, pp. 1051-66.
44. Zucker, LG and Darby, MR and Armstrong, JS. (2002) Commercializing knowledge: University science, knowledge capture, and firm performance in biotechnology Management Science, 48, pp. 138-53.
45. Zucker, LG and Darby, MR and Brewer, M. (1998) Intellectual human capital and the birth of US biotechnology enterprises American Economic Review, 88, pp. 290-306.